Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets.

NPJ Breast Cancer · 2023 · PMC10693625 · PMID 38042915

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Cellular viability was significantly reduced also in MCF7 blue TAMR_1 and red LTED_5 clones upon treatment with 2.50 μM Sotrastaurin and showed a trend when compared to Sotrastaurin-treated +E2_5 control cells (Fig. 6c ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.